Table 1. Description of the Subcohorts, Inclusion and Exclusion Criteria, and Entry and End Dates of Follow-up Used to Calculate Person-Time of Exposure.

Cohort	Inclusion criteria	Exclusion criteria	Entry date	End date of follow-up
GD with GnRHa	At least 1 GD diagnosis (ICD-10 codes F64.0, F64.8, or F64.9) in the NPR and treatment with GnRHa (ATC codes H01CA or L02AE in the PDR) after or within 2 y before the first GD diagnosis	IIH diagnosis (ICD-10 code G93.2 in the NPR) before GD diagnosis	Date of first dispensed prescription for GnRHa	The earliest date of first IIH diagnosis, date of death, date of emigration, or end of studya
GD without GnRHa	At least 1 GD diagnosis	IIH diagnosis before GD diagnosis	Date of first GD diagnosis	The earliest date of first IIH diagnosis, first dispensed GnRHa prescription, date of death, date of emigration, or end of studya
General population without GD or GnRHa	20 Randomly selected individuals from general population for each selected individual with GD, matched for age, same- and opposite- assigned sex at birth, and county of residence	Lifetime GD diagnosis, IIH diagnosis before entry date, or GnRHa prescription before entry date	Date of first GD diagnosis of the matched person	The earliest date of first IIH diagnosis, first dispensed GnRHa prescription, date of death, date of emigration, or end of studya

Abbreviations: ATC, Anatomical Therapeutic Chemical; GD, gender dysphoria; GnRHa, gonadotropin-releasing hormone analogue; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; IIH, idiopathic intracranial hypertension; NPR, National Patient Register; PDR, Prescribed Drug Register.

^a End of study was December 31, 2016.